Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Early Phase 1

6(75.0%)

Phase 1

1(12.5%)

Phase 2

1(12.5%)

8Total

Early Phase 1(6)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07489196Phase 2Not Yet Recruiting

A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

Role: lead

NCT06024876Early Phase 1Completed

A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia

Role: lead

NCT07176923Early Phase 1Recruiting

CS-121 APOC3 Base Editing in FCS

Role: lead

NCT06565026Early Phase 1Recruiting

CS-206 in Patients With Sickle Cell Disease

Role: lead

NCT06328764Early Phase 1Enrolling By Invitation

CS-101 in Patients With β-thalassemia

Role: lead

NCT06291961Phase 1Completed

A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

Role: lead

NCT06685536Enrolling By Invitation

A Long-term Follow-up Study in Participants Who Received CS-101

Role: lead

NCT06717932Enrolling By Invitation

A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection

Role: lead

NCT07371767Early Phase 1Recruiting

CS-121 APOC3 Base Editing in Children and Adolescents With Hyperchylomicronemia

Role: collaborator

NCT06065189Early Phase 1Active Not Recruiting

Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major

Role: collaborator

All 10 trials loaded